Journal of Developing Drugs
Open Access
ISSN: 2329-6631
+44 1478 350008
ISSN: 2329-6631
+44 1478 350008
Department of Liver Diseases, Shuguang Hospital affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China
Research Article
The Efficacy of Treating Pulmonary Fibrosis and Pulmonary Function Injury in COVID-19 with Fuzheng Huayu Tablets: Study Protocol for a Multicenter Randomized Controlled Trial
Author(s): Fei Jing*, Haina Fan, Zhimin Zhao, Feng Xing, Yingchun He, Chenghai Liu, Chenghai Liu and Chenghai Liu
Introduction: The patients with COVID-19 could be suffered from pulmonary dysfunction and/or fibrosis in recovery period, but there are no certain drugs or treatment to cope with this situation. Our previous studies indicated that Fuzheng Huayu tablets (FZHY) could regress lung fibrosis induced by bleomycin in animals, and improve pulmonary function in patients with chronic obstructive pulmonary disease. Now we design this trial in order to evaluate the effects of FZHY on pulmonary fibrosis and/or pulmonary function injury in the recovery period of COVID-19 and expect to improve the prognosis.
Methods and analysis: This is a randomized, double-blinded, multicenter, placebo-controlled clinical trial from March 1, 2020 to December 31, 2021. 160 patients who had been diagnosed with COVID-19 were enrolled, but currently they are negative in vira.. View More»
DOI:
10.35248/2329-6631.21.10.205